Lercanidipine Hcl Amarox

Lercanidipine, the active ingredient in Lercanidipine Hcl Amarox, is a calcium channel blocker presented as a tablet for oral use. It lowers elevated blood pressure by relaxing vascular smooth muscle, and is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Lercanidipine Hcl Amarox as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and serving hospitals, pharmacies and clinics worldwide with reliable, bulk‑ready shipments. The product is manufactured under strict quality control and is available in various packaging sizes for global distribution.

Lercanidipine is a calcium channel blocker used to manage hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers both systolic and diastolic blood pressure, helping to achieve target levels in adult patients. - Essential hypertension: provides sustained vasodilation, contributing to long‑term control of primary high blood pressure. - Isolated systolic hypertension: reduces elevated systolic pressure, particularly in older adults where pulse pressure is high. - High cardiovascular risk patients: when combined with other antihypertensives, it assists in overall risk management.

Lercanidipine may cause a range of adverse reactions. Most are mild and reversible, but rare serious events can occur.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually temporary. - Peripheral edema: swelling of ankles or lower limbs due to fluid accumulation. - Dizziness: light‑headed feeling, especially after standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue or throat that may compromise airway. - Liver injury: abnormal liver enzymes or hepatitis, necessitating monitoring.

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: check baseline and periodic readings before and during therapy. - Cardiovascular status: avoid in patients with unstable angina or recent myocardial infarction. - Liver function: assess hepatic impairment before initiating. - Elderly patients: start at lower dose and monitor for edema. - Drug interactions: review concomitant medications that affect CYP3A4. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Lercanidipine can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Grapefruit juice: can raise drug concentration.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood pressure lowering effect. - Diuretics: may enhance antihypertensive effect, monitor electrolytes. - ACE inhibitors/ARBs: combined therapy may increase risk of hypotension.